Last A$0.0010 AUD
Change Today 0.00 / 0.00%
Volume 0.0
ACU On Other Exchanges
Symbol
Exchange
Frankfurt
As of 2:16 AM 03/21/14 All times are local (Market data is delayed by at least 15 minutes).

acuvax ltd (ACU) Snapshot

Open
--
Previous Close
A$0.0010
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
A$-0.0005
Shares Outstanding
2.6B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACUVAX LTD (ACU)

Related News

No related news articles were found.

acuvax ltd (ACU) Related Businessweek News

No Related Businessweek News Found

acuvax ltd (ACU) Details

Acuvax Limited, through its subsidiaries, primarily researches and develops cancer therapies in Australia. It is also involved in the development of virus and vaccines. The company was formerly known as Avantogen Limited. Acuvax Limited is based in West Perth, Australia.

acuvax ltd (ACU) Top Compensated Officers

Founder, Chief Scientific Officer of Adjuvant...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Chief Operating Officer and Director Nominee
Total Annual Compensation: --
Company Secretary and Non Executive Director
Total Annual Compensation: --
General Counsel
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

acuvax ltd (ACU) Key Developments

Acuvax Ltd. Appoints Alex Bajada as Non Executive Director

Acuvax Ltd. announced the appointment of Alex Bajada as a non executive director of the company. Mr. Bajada has long term experience as both Chairman and director of several ASX listed companies, including the role of Deputy Chair of Advance Healthcare Ltd. Mr. Bajada shortly completes over 20 years as a director and at certain times chairman of WA Super Ltd. As a result Mr. Bajada should be available to commit to assisting in the development of Acuvax Ltd. projects. Mr. Bajada is also a non executive director of private equity fund Hawkesbridge Ltd. and Wesmaem Ltd.

Acuvax Announces Resignation of Anton Uvarov as a Non-Executive Director from the Board

Dr. Anton Uvarov has resigned as a Non-Executive Director from the board of Acuvax.

Acuvax Limited Reports Consolidated Earnings Results for the First Half Year Ended Dec. 31, 2013

Acuvax Limited reported consolidated earnings results for the first half year ended Dec. 31, 2013. For the first half, the company reported loss before income tax of AUD 541,467 and loss for the period attributable to members of the parent company of AUD 530,427 or 0.023 cents per diluted share on total revenue of AUD 6,862 against loss before income tax of AUD 237,744 and loss for the period attributable to members of the parent company of AUD 226,704or 0.010 cents per diluted share on total revenue of AUD 10,845 for the same period of last year. Net cash used in operating activities was AUD 130,797 against AUD 216,977 for the same period of last year. Purchase of property, plant and equipment was AUD 112,081 against AUD 184,336 for the same period of last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACU:AU A$0.00 AUD 0.00

ACU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACU.
View Industry Companies
 

Industry Analysis

ACU

Industry Average

Valuation ACU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 740.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 776.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACUVAX LTD, please visit www.acuvax.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.